Moderna announces submission of initial data to U.S. FDA for its COVID-19 vaccine booster

Moderna

1 September 2021 - mRNA-1273 at 50 µg dose level induced robust antibody responses of more than 40x against the Delta variant (B.1.617.2).

Moderna today announced it has initiated its submission to the U.S. FDA for the evaluation of a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg dose level. 

The Company expects to submit data to the EMA and other regulatory authorities around the world in the coming days.

Read Moderna press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Vaccine , Dossier , COVID-19